Lancet: Compared to the efficacy of three MET kinase inhibitors for metastatic pap-shaped renal cell carcinoma

Met (also known as hepatocellular growth factor complex) signaling is a key driver of papicular renal cell carcinoma (PRCC).
In view of the fact that there is no best treatment for metastasis PRCC, the goal of this study is to compare the existing treatment standards, namely sunitinib and metase inhibitors Cabozantinib, crizotinib and savolitinib for the treatment of PRCC patients.
a randomized, open-label Phase II trial at 65 centers in the United States and Canada.
patients who had received at most one treatment (excluding vascular enditer growth factor targeting and MET targeted drugs) aged 18 or older were recruited.
patients were randomly assigned to receive shonitinib, carbotinib, clotinib, or savolitinib, strated according to past treatment history and PRCC subsype.
all medications are taken ornithotic: schoinib 50 mg for 4 weeks, suspended for 2 weeks (reduced to 37.5 mg and 25 mg); Clotinib 250 mg 2 times/day (reduced to 200 mg/day and 250 mg/day); savolitinib 600 mg/day (reduced to 400 mg and 200 mg).
end point is progress-free lifetime (PFS).
between April 5, 2016 and December 15, 2019, 152 patients were randomly assigned to four groups.
five patients were identified as ineligible and excluded from these analyses.
After a pre-specified ineffective analysis, the allocation of patients to the savolitinib group (29 patients) and the kerptinib group (28 patients) group was discontinued, and the Schoinib group (46 patients) and the cabotinib group (44 patients) achieved the planned benefits.
PFS in the Cabotini group was significantly longer than in the Schoini group (medium value 9.0 vs 5.6 months; progression or death risk ratio was 0.60, 95% CI 0.37 to 0.97, one-sided p=0.019).
23 per cent effectiveness of kabotini, while the effective rate of Schoini is only 4 per cent (two-sided p-0.010).
compared to savolitinib and clotinib did not improve the patient's PFS.
31 (69%) of the 45 patients treated with schoinib had level 3 or 4 adverse events, 32 (74%) of the 43 patients treated with capodinib had level 3 or 4 adverse events, and 27 received kerazine Ten (37%) of the patients treated with tinib had level 3 or 4 adverse events, 11 (39%) of the 28 patients treated with savolitinib had level 3 or 4 adverse events, and the Cabotinib group had a level 5 thromboembolism event.
, metastasis PRCC patients received significantly longer PFS after treatment with cabotinib than Schoini.